Home Blog of Signal Transduction Cell Cycle PD-1/PD-L1

Category

Archives

Popular Post

ESKM, a novel therapeutic agent for sensitive and resistant PH+ leukemias

The mechanism of resistance to JAK2 inhibitor in myeloproliferative neoplasms patients

Effects of PARP inhibitors in BRCA gene-mutated ovarian cancer

DASATINIB; An inhibitor of Receptor Tyrosine Kinase

GP130/JAK/STAT3 signaling pathway induces multiple myeloma

PD-1/PD-L1

Targeting cryptic-orthosteric site of PD-L1 for inhibitor identification using structure-guided approach

135 views | Sep 03 2023

This study utilized structure-assisted virtual screening and molecular dynamics simulations to identify two novel small molecule compounds as potential therapeutic candidates for inhibiting the PD-L1 protein-protein interaction in cancer treatment. [Read the Full Post]

CSF-1R inhibitor, pexidartinib, sensitizes esophageal adenocarcinoma to PD-1 immune checkpoint blockade in a rat model

0 views | Aug 11 2023

This study demonstrates that pexidartinib, a CSF-1R inhibitor, alone or in combination with a PD-1 inhibitor, shows significant tumor shrinkage and enhanced antitumor immune responses in a rat model of esophageal adenocarcinoma, providing a promising combinatorial strategy for future clinical approaches. [Read the Full Post]

Treatment with eFT-508 increases chemosensitivity in breast cancer cells by modulating the tumor microenvironment

212 views | Jul 26 2023

Tomivosertib (eFT-508) demonstrates promising efficacy both in vitro and in vivo, including synergistic effects with adriamycin, suggesting its potential as a more efficacious therapeutic option for patients with triple-negative breast cancer (TNBC). [Read the Full Post]

MAPK-interacting kinases inhibition by eFT508 overcomes chemoresistance in preclinical model of osteosarcoma

274 views | Jul 26 2023

The study highlights the therapeutic potential of eFT508, a selective inhibitor of MNK1/2, alone and in combination with paclitaxel, as a promising treatment for osteosarcoma by inhibiting tumor growth and demonstrating selectivity and synergistic effects. [Read the Full Post]

A retrospective cohort study on the efficacy and safety for combination therapy of immunotherapy, targeted agent, and chemotherapy versus immunochemotherapy or chemotherapy alone in the first-line treatment of advanced biliary tract carcinoma

79 views | Jul 05 2023

This retrospective study suggests that combining anti-PD-1/PD-L1 immunotherapy with anlotinib and gemcitabine shows promising efficacy and an acceptable safety profile in patients with advanced biliary tract carcinoma. [Read the Full Post]

Targeting glutamine metabolism with photodynamic immunotherapy for metastatic tumor eradication

100 views | Jul 04 2023

The study presents a novel photodynamic immunostimulant, BVC, that reprograms glutamine metabolism and combines immune checkpoint blockade therapy with photodynamic therapy to enhance immune recognition and prevent immune escape for the eradication of metastatic tumors. [Read the Full Post]

Proof of concept nanotechnological approach to in vitro targeting of malignant melanoma for enhanced immune checkpoint inhibition

103 views | Jul 04 2023

The study demonstrates that the delivery of a small molecule inhibitor of the PD-1/PD-L1 pathway using nanodiamond-based nanoparticles enhances immune cell stimulation and promotes stronger interactions between immune cells and melanoma cells, suggesting potential for improved melanoma therapy. [Read the Full Post]

Design, synthesis, and evaluation of PD-1/PD-L1 small-molecule inhibitors bearing a rigid indane scaffold

131 views | Jul 04 2023

Compound D3, a novel small-molecule inhibitor of the PD-1/PD-L1 interaction, demonstrates potent inhibitory activity and immune-enhancing effects, making it a promising candidate for further development in immunotherapy. [Read the Full Post]

Treatment-related adverse events of PD-1/PD-L1 inhibitors combined with CTLA-4 inhibitors in clinical trials: a meta-analysis

98 views | Oct 16 2022

Ze Mi et al. thought that PD-L1 inhibitors plus CTLA-4 inhibitors showed better safety in treatment-related adverse events than PD-1 inhibitors plus CTLA-4 inhibitors. [Read the Full Post]

Effects of Elexacaftor/Tezacaftor/Ivacaftor Therapy on Lung Clearance Index and Magnetic Resonance Imaging in Patients with Cystic Fibrosis and One or Two F508del Alleles

242 views | May 12 2022

Simon Y Graeber et al. found that improvement of CFTR function by ELX/TEZ/IVA improved lung ventilation and abnormalities in lung morphology including airway mucus plugging and wall thickening in adolescent. [Read the Full Post]